Glaukos (NYSE:GKOS) Trading 6% Higher on Analyst Upgrade

Shares of Glaukos Corporation (NYSE:GKOS) traded up 6% during trading on Wednesday after BTIG Research raised their price target on the stock from $123.00 to $131.00. BTIG Research currently has a buy rating on the stock. Glaukos traded as high as $128.84 and last traded at $125.8350. 274,089 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 868,016 shares. The stock had previously closed at $118.70.

A number of other brokerages also recently commented on GKOS. Piper Sandler reiterated an “overweight” rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. UBS Group lifted their price target on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. The Goldman Sachs Group reissued a “buy” rating and issued a $138.00 price objective on shares of Glaukos in a report on Friday, January 9th. Stifel Nicolaus increased their price target on shares of Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.54.

Insider Buying and Selling

In other news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director directly owned 34,905 shares in the company, valued at $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 315 shares of the stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the transaction, the chief financial officer directly owned 50,488 shares of the company’s stock, valued at $5,301,240. This represents a 0.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 329,655 shares of company stock worth $37,752,234. 5.80% of the stock is currently owned by insiders.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: FDA approves re-administration of iDose TR — Approval increases the product’s commercial flexibility and addressable market (potential for repeat treatments and improved lifetime value per patient), which was the primary catalyst for the intraday rally. Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
• Positive Sentiment: Analyst price-target increase from BTIG — BTIG raised its target to $131 and keeps a Buy rating, implying roughly double-digit upside from current levels and signaling continued analyst confidence in growth from interventional glaucoma products. GKOS price target raised by BTIG
• Positive Sentiment: Zacks reiterates hold/retain thesis highlighting iDose and iStent synergy and scale benefits — Zacks notes growing adoption of interventional glaucoma and operating-leverage potential, suggesting upside as revenue scales despite near-term margin pressure. Here’s Why You Should Retain Glaukos Stock in Your Portfolio Now
• Neutral Sentiment: Consensus rating sits at “Moderate Buy” — The analyst consensus supports modest upside but stops short of unanimous conviction; useful context but not a fresh catalyst on its own. Glaukos Given Consensus Rating of “Moderate Buy” by Analysts
• Negative Sentiment: Recent insider sales — Two named insiders sold shares (Joseph Gilliam ~10,498 shares; Marc Stapley ~15,000 shares). Insider selling can be interpreted as a near-term negative signal for sentiment, even if sales may be for personal/liquidity reasons. Joseph Gilliam Sells 10,498 Shares Marc Stapley Sells 15,000 Shares

Institutional Investors Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. lifted its stake in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 158 shares during the period. First Horizon Corp lifted its position in shares of Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 223 shares during the period. REAP Financial Group LLC acquired a new stake in shares of Glaukos in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC raised its holdings in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 215 shares during the last quarter. Finally, Salomon & Ludwin LLC raised its holdings in Glaukos by 111.2% during the fourth quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 239 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Performance

The company has a market capitalization of $6.83 billion, a PE ratio of -77.17 and a beta of 0.67. The stock has a 50-day simple moving average of $112.81 and a 200 day simple moving average of $96.75. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same period last year, the firm posted ($0.28) EPS. Equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.